Ovid Therapeutics announced Phase 1 study results for OV350, the first-ever direct activator of KCC2.
OV350 demonstrated a good safety profile with no treatment-related adverse events.
Results support Ovid's KCC2 portfolio advancement, including the oral direct activator, OV4071.
Safety and Tolerability
OV350 showed no treatment-related adverse events and had a good safety profile.
Pharmacokinetics
Results informed dosing strategies for future KCC2 development programs.
Portfolio Advancement
Results support the development of additional direct activator molecules, including OV4071.
Clinical Trial Progress
OV4071 is on track for a Phase 1/1b clinical trial submission in Q1 2026.
- The Phase 1 study confirmed OV350's safety and efficacy, paving the way for future clinical developments.
- Results support the potential of KCC2 direct activators, enhancing Ovid's therapeutic portfolio.
- OV4071's advancement signals promising prospects for treating neurological disorders.
- The study outcomes position Ovid as a key player in developing innovative treatments for brain disorders.
OV350's Phase 1 study results demonstrate promising safety and efficacy, driving Ovid's commitment to advancing neurotherapeutics. The success of OV4071 and the positive pharmacokinetic data further solidify Ovid's position in the field of brain disorder treatments.